Intravenous recombinant tissue-type plasminogen activator is a recommended pharmacological effective therapy (National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995; Powers et al., 2018); however, there is though it not only has strict therapeutic time window but also may cause serious complications such as hemorrhage (Sandercock et al., 2012; Berge et al., 2016; Demaerschalk et al., 2016). The gene discussed is PLAT; the disease is stroke disorder.